Titan Pharmaceuticals Completes Merger with Black Titan Corporation, Creating New Nasdaq-Listed Entity
核心洞察
Titan Pharmaceuticals successfully completed its merger with Black Titan Corporation (搜索) on October 1, 2025, becoming a wholly owned subsidiary of the combined entity.
The merged company's ordinary shares began trading on Nasdaq under the ticker symbol BTTC on October 2, 2025, following a one-for-one share conversion.
Black Titan CEO Chay W. J. described the merger as the beginning of a new chapter focused on innovation and global expansion to deliver transformative stakeholder value.
Titan Pharmaceuticals has successfully completed its previously announced merger with Black Titan Corporation (搜索) and TalenTec Sdn. Bhd. (搜索), creating a new pharmaceutical entity that began trading on Nasdaq on October 2, 2025. The transaction, which closed on October 1, 2025, positions the combined company for expanded innovation and global reach in the pharmaceutical sector.
Merger Structure and Trading Details
Under the terms of the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan Pharmaceuticals became a wholly owned subsidiary of Black Titan Corporation (搜索). Each issued and outstanding share of Titan common stock was automatically converted into ordinary shares of Black Titan on a one-for-one basis.
The combined company's ordinary shares, with a par value of $0.0001 per share, now trade on the Nasdaq stock exchange under the ticker symbol BTTC. Trading of Titan's common stock on the Nasdaq Capital Market ceased at the close of business on October 1, 2025, with Black Titan's ordinary shares commencing trading the following day.
Strategic Vision and Leadership
Chay W. J., CEO of Black Titan, emphasized the strategic significance of the merger beyond its structural implications. "This merger represents more than a structural change, it's the beginning of a new chapter of innovation and global expansion," he stated. "We are well-positioned to execute our strategic vision and bring transformative value to our stakeholders."
Transaction Advisory
ARC Group Ltd. (搜索) served as the exclusive financial advisor to Black Titan Corporation (搜索) throughout the merger process, facilitating the successful completion of this pharmaceutical industry consolidation.
The merger represents a significant corporate restructuring in the pharmaceutical sector, combining the resources and capabilities of multiple entities under the Black Titan umbrella to pursue enhanced innovation and market expansion opportunities.